An alternative route to pertussis protection?

Affiliations

¹ Vanderbilt University Medical Center, Nashville, TN 37221, USA. Electronic address: kathryn.edwards@vumc.org.
² Vanderbilt University Medical Center, Nashville, TN 37221, USA.

Comment

Kathryn M Edwards et al. Lancet. 2023.

. 2023 Mar 11;401(10379):800-801.

doi: 10.1016/S0140-6736(23)00225-8.

¹ Vanderbilt University Medical Center, Nashville, TN 37221, USA. Electronic address: kathryn.edwards@vumc.org.
² Vanderbilt University Medical Center, Nashville, TN 37221, USA.

No abstract available

Comment on

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
Keech C, Miller VE, Rizzardi B, Hoyle C, Pryor MJ, Ferrand J, Solovay K, Thalen M, Noviello S, Goldstein P, Gorringe A, Cavell B, He Q, Barkoff AM, Rubin K, Locht C. Keech C, et al. Lancet. 2023 Mar 11;401(10379):843-855. doi: 10.1016/S0140-6736(22)02644-7. Lancet. 2023. PMID: 36906345 Clinical Trial.